In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

"New-onset atrial fibrillation efter cardiac surgery is associated with increased long-term morbidity and mortality": a population-based study from the SWEDEHEART-registry.

Session Factors affecting prognosis of CABG patients

Speaker Amar Taha

Congress : ESC Congress 2019

  • Topic : interventional cardiology and cardiovascular surgery
  • Sub-topic : Cardiovascular Surgery - Arrhythmias
  • Session type : Abstract Session
  • FP Number : 2225

Authors : A Taha (Goeteborg,SE), A Jeppsson (Goeteborg,SE), L Friberg (Stockholm,SE), S Nielsen (Gothenburg,SE), A Ahlsson (Stockholm,SE), S Bjorck (Gothenburg,SE), L Bergfeldt (Gothenburg,SE)

Authors:
A Taha1 , A Jeppsson1 , L Friberg2 , S Nielsen3 , A Ahlsson4 , S Bjorck5 , L Bergfeldt3 , 1Sahlgrenska University Hospital - Goteborg - Sweden , 2Danderyd University Hospital - Stockholm - Sweden , 3University of Gothenburg - Gothenburg - Sweden , 4Karolinska University Hospital - Stockholm - Sweden , 5National Diabetes Register Centre - Gothenburg - Sweden ,

Citation:

Background:New-onset postoperative atrial fibrillation (POAF) is a common complication after cardiac surgery, but the prognostic implications are not settled. In contrast to previous reports, a recent Danish study in coronary bypass surgery (CABG) patients (Butt et al. JAMA Cardiol 2018) did not show any increased risk for thromboembolic complications in POAF patients. 

Purpose:To compare long-term outcome in patients with vs. without POAF after CABG. 

Methods:All CABG patients in Sweden 2005-2015 (n=38040) were included in a retrospective population-based cohort study. Data from the SWEDEHEART registry, the National Patient Registry and the National Population Registry were merged. POAF was defined as any new-onset atrial fibrillation (AF) episode up to the 30thpostoperative day. Inverse Probability Treatment Weighting (IPTW) adjusted Cox regression models were used to compare outcome variables after the first 30 postoperative days until the end of follow-up (median 5 years, range 0-10). The models were adjusted for age, gender, CHA2DS2-VASc score, co-morbidity, and medications. 

ResultsThe mean age of the entire cohort was 68 years, 79% were men and 90% had a CHA2DS2-VASc score =2. The incidence of POAF was 28.5% (10845/38040). During follow-up POAF, patients had a significantly higher adjusted risk for all-cause mortality [Hazard Ratio (HR) 1.16 (95 % CI 1.09-1.24)], ischemic stroke [HR 1.19 (1.09-1.30)], transient ischemic attack [HR 1.17 (1.03-1.33)], pulmonary embolism [HR 1.24 (1.01-1.54)], myocardial infarction [HR 1.14 (1.04-1.25)], heart failure hospitalizations [HR.1.46 (1.35-1.59)] and recurrent AF [HR 4.33 (4.09-4.65)].

Conclusions POAF was in this comparatively large study associated with increased risk for mortality and morbidity during long-term follow-up after CABG and is hence not a trivial complication.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are